Trials / Completed
CompletedNCT00404014
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- Allon Therapeutics · Industry
- Sex
- All
- Age
- 50 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL-208 | 1 dose of 300 mg |
| DRUG | Placebo | 1 dose of placebo |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-11-27
- Last updated
- 2012-10-24
Locations
28 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00404014. Inclusion in this directory is not an endorsement.